Market Cap 52.78M
Revenue (ttm) 19.65M
Net Income (ttm) -7.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -38.52%
Debt to Equity Ratio -0.92
Volume 220,900
Avg Vol 156,192
Day's Range N/A - N/A
Shares Out 32.19M
Stochastic %K 77%
Beta 1.18
Analysts Strong Sell
Price Target $4.75

Company Profile

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States. The company offers DeepView System, which uses proprietary AI algorithms to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye at the initial time point of wound presentation and delivers a binary prediction on the wounds capacity to heal by a specified time point in the future to assist the physician in...

Industry: Medical Devices
Sector: Healthcare
Phone: 972 499 4934
Address:
2515 McKinney Avenue, Suite 1000, Dallas, United States
afterhoursearnings
afterhoursearnings Sep. 19 at 12:58 AM
$MDAI intraday time frames looking quite strong in terms of stochisstics, moving average crosses, A/D, and ADX. Hit our head on the 50ema on the daily. If we pop that with some force maybe we get some follow through on the weekly to the 200ema (around 4).
0 · Reply
MoneySwell
MoneySwell Sep. 18 at 8:06 PM
$MDAI Interesting… 105,000 shares (half the day’s volume) traded in the last 15 minutes. Pushing the price up to close near the high of the day.👍🏼
1 · Reply
MoneySwell
MoneySwell Sep. 18 at 3:41 PM
$MDAI Spectral Al Showcases DeepView® System for Burn Indication and KOL Research at Southern Regional Burn Conference (SRBC). ( held September 10-12, 2026 in Williamsburg, Virginia.) Upcoming events: Midwest Region Burn Conference (MRBC) October 22-23, 2026 Columbus, OH Northeast Region Burn Conference (NRBC) November 13-14, 2026 Boston, MA https://finance.yahoo.com/healthcare/articles/spectral-ai-showcases-deepview-system-201500677.html
0 · Reply
CorbettCM
CorbettCM Sep. 18 at 3:19 PM
0 · Reply
Latinoheart
Latinoheart Sep. 18 at 10:07 AM
$MDAI @CorbettCM Spectral IP was created in 2024 as a separately funded intellectual-property venture, supported by a $1 million loan from its largest shareholder. Management presented it as a potential source of additional shareholder value without using capital earmarked for the core DeepView business. The company later proposed spinning off Spectral IP and distributing shares to Spectral AI shareholders. A March 2025 SEC filing expanded the plan, outlining an IPO, patent-related investments, licensing opportunities and other IP-focused activities. However, the proposed IPO and shareholder distribution never occurred. In July 2026, Spectral IP withdrew its registration statement and confirmed no securities had been sold. As a result, key questions remain unanswered: the status of the original $1 million loan, what assets and transactions were completed, Spectral AI's current ownership and economic interest in Spectral IP, and whether any alternative plans remain under consideration.
0 · Reply
Latinoheart
Latinoheart Sep. 18 at 10:02 AM
$MDAI @CorbettCM Strategic and commercial relationships. Spectral AI has highlighted the development of strategic relationships with government and commercial partners as an important part of its growth strategy. In August 2026, the company reported receiving $31.7 million in advanced BARDA funding and confirmed completion of all remaining milestones under its MTEC contract, including delivery of a functioning handheld DeepView prototype. These achievements are significant but should be distinguished from commercial product sales and private-sector distribution agreements. Based on the public announcements reviewed, I have not identified a disclosed material distribution agreement, minimum-purchase commitment, or separately reported commercial product revenue linked to a named commercial partner. The available public information does not allow shareholders to assess the commercial value, expected revenue, or maturity of the partnerships referenced.
0 · Reply
Latinoheart
Latinoheart Sep. 18 at 10:00 AM
$MDAI @CorbettCM Four DeepView platforms. In March 2025, management stated that it believed the company was on the proper path to generate commercial revenue from four separate DeepView platforms covering burns and other indications within three years. That remains a forward-looking objective. On the announced timetable, the three-year period had not expired by 14 September 2026. The materials reviewed do not, however, provide a simple platform-by-platform explanation identifying all four platforms and setting out the development, regulatory and commercial position of each one. Clear milestones for each platform would help shareholders assess progress without treating a long-term objective as either completed or missed before the stated period has expired.
0 · Reply
Latinoheart
Latinoheart Sep. 18 at 9:59 AM
$MDAI @CorbettCM Wound measurement. Management also stated in November 2023 that it intended to submit applications during 2024 for FDA, UKCA and CE-mark approval of 3D wound-measurement capabilities, subject to completion of the relevant development and regulatory work. Later company announcements referred to continuing technology development, including completion of a proof-of-concept module for calculating the total body surface area of a burn. However, the public filings and announcements reviewed do not clearly confirm the outcome of all the regulatory applications contemplated for wound measurement or identify a separately commercialised wound-measurement product. This does not prove that the programme has ended. It means that shareholders would benefit from a direct update on its regulatory position, remaining development work and commercial timetable.
0 · Reply
Latinoheart
Latinoheart Sep. 18 at 9:58 AM
$MDAI @CorbettCM DeepView for diabetic foot ulcers was a key part of Spectral AI’s post-SPAC growth strategy. In November 2023, management stated that it expected to submit FDA, UKCA and CE-mark applications for the DeepView DFU indication during 2024. By May 2024, the company reported completion of enrolment in its US DFU training study, expected completion of the validation study in the second half of 2024, and completion of a separate 76-patient study in Ireland. Current company materials continue to highlight the DFU opportunity and state that DeepView achieved 86% accuracy in predicting whether a DFU would achieve 50% wound closure by week four. However, based on publicly available information reviewed, it is unclear whether the FDA, UKCA and CE-mark applications anticipated for 2024 were submitted, approved, or remain under review. The current regulatory status, development timeline and route to commercialisation are not clearly disclosed.
0 · Reply
Latinoheart
Latinoheart Sep. 18 at 9:54 AM
$MDAI @CorbettCM Commercial revenue timeline. Since its September 2023 Nasdaq listing, Spectral AI has repeatedly linked DeepView commercialisation to near-term revenue. In 2023, management indicated a potential launch as early as 2024, subject to approvals. Following UKCA authorisation in February 2024, the company stated that UK sales could begin and expected commercial revenue during H2 2024. This expectation was reiterated in May 2024. By March 2025, management instead guided to first commercial product revenue in H2 2025. In May 2026, the FDA granted De Novo clearance for DeepView's burn indication, enabling US commercial distribution. The company subsequently stated it expects first US commercial sales by the end of 2026. These milestones relate to different markets and revenue categories, so they are not directly comparable. However, investors would benefit from clearer disclosure on the outcome of the UK revenue expectations announced for 2024 and discussed in 2025.
0 · Reply
Latest News on MDAI
Spectral AI Earnings Call Transcript: Q2 2026

Aug 11, 2026, 5:00 PM EDT - 5 weeks ago

Spectral AI Earnings Call Transcript: Q2 2026


Spectral AI Quarterly report: Q2 2026

Aug 11, 2026, 5:00 PM EDT - 5 weeks ago

Spectral AI Quarterly report: Q2 2026


Spectral AI Earnings release: Q2 2026

Aug 11, 2026, 5:00 PM EDT - 5 weeks ago

Spectral AI Earnings release: Q2 2026


Spectral AI Announces 2026 Second Quarter Financial Results

Aug 11, 2026, 4:05 PM EDT - 5 weeks ago

Spectral AI Announces 2026 Second Quarter Financial Results


Spectral AI transferred with an Outperform at Northland

2026-07-27T13:25:20.000Z - 7 weeks ago

Spectral AI transferred with an Outperform at Northland


Spectral AI names Darcy Bajko chief commercial officer

2026-07-08T13:15:22.000Z - 2 months ago

Spectral AI names Darcy Bajko chief commercial officer


Spectral AI price target raised to $4 from $3 at BTIG

2026-05-26T23:15:07.000Z - 3 months ago

Spectral AI price target raised to $4 from $3 at BTIG


Spectral AI receives FDA De Novo clearance for DeepView System

2026-05-26T11:53:02.000Z - 3 months ago

Spectral AI receives FDA De Novo clearance for DeepView System


Spectral AI Earnings Call Transcript: Q1 2026

May 12, 2026, 5:00 PM EDT - 4 months ago

Spectral AI Earnings Call Transcript: Q1 2026


Spectral AI Earnings release: Q1 2026

May 12, 2026, 5:00 PM EDT - 4 months ago

Spectral AI Earnings release: Q1 2026


Spectral AI Quarterly report: Q1 2026

May 12, 2026, 5:00 PM EDT - 4 months ago

Spectral AI Quarterly report: Q1 2026


Spectral AI Announces 2026 First Quarter Financial Results

May 12, 2026, 4:10 PM EDT - 4 months ago

Spectral AI Announces 2026 First Quarter Financial Results


Spectral AI Announces Annual Meeting of Stockholders

Apr 20, 2026, 4:15 PM EDT - 5 months ago

Spectral AI Announces Annual Meeting of Stockholders


Spectral AI Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 5 months ago

Spectral AI Proxy statement: Proxy filing


Spectral AI Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 5 months ago

Spectral AI Proxy statement: Proxy filing


Spectral AI appoints David McGuire as CFO

2026-04-08T13:01:46.000Z - 5 months ago

Spectral AI appoints David McGuire as CFO


Spectral AI Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 5 months ago

Spectral AI Proxy statement: Proxy filing


Spectral AI Earnings Call Transcript: Q4 2025

Mar 24, 2026, 5:00 PM EDT - 6 months ago

Spectral AI Earnings Call Transcript: Q4 2025


Spectral AI Annual report: Q4 2025

Mar 24, 2026, 5:00 PM EDT - 6 months ago

Spectral AI Annual report: Q4 2025


Spectral AI Earnings release: Q4 2025

Mar 24, 2026, 5:00 PM EDT - 6 months ago

Spectral AI Earnings release: Q4 2025


Spectral AI reports Q4 EPS 2c with items, consensus (14c)

2026-03-24T20:30:43.000Z - 6 months ago

Spectral AI reports Q4 EPS 2c with items, consensus (14c)


Spectral AI sees FY26 revenue $18.5M, consensus $14.08M

2026-03-24T20:30:33.000Z - 6 months ago

Spectral AI sees FY26 revenue $18.5M, consensus $14.08M


Spectral AI appoints Capone as CEO

2026-02-10T13:36:41.000Z - 7 months ago

Spectral AI appoints Capone as CEO


Spectral AI Names Vincent S. Capone as Chief Executive Officer

Feb 10, 2026, 8:30 AM EST - 7 months ago

Spectral AI Names Vincent S. Capone as Chief Executive Officer


DeepView™ System Featured at 2025 US Burn Conferences

Nov 19, 2025, 8:00 AM EST - 10 months ago

DeepView™ System Featured at 2025 US Burn Conferences


Spectral AI Earnings Call Transcript: Q3 2025

Nov 11, 2025, 5:00 PM EST - 10 months ago

Spectral AI Earnings Call Transcript: Q3 2025


Spectral AI Quarterly report: Q3 2025

Nov 11, 2025, 5:00 PM EST - 10 months ago

Spectral AI Quarterly report: Q3 2025


Spectral AI Earnings release: Q3 2025

Nov 11, 2025, 5:00 PM EST - 10 months ago

Spectral AI Earnings release: Q3 2025


Spectral AI reports Q3 EPS (13c), consensus (9c)

2025-11-11T21:05:49.000Z - 10 months ago

Spectral AI reports Q3 EPS (13c), consensus (9c)


Spectral AI Announces 2025 Third Quarter Financial Results

Nov 11, 2025, 4:00 PM EST - 10 months ago

Spectral AI Announces 2025 Third Quarter Financial Results


Spectral AI Registration statement: Registration Filing

Oct 30, 2025, 8:00 AM EDT - 10 months ago

Spectral AI Registration statement: Registration Filing


Spectral AI prices 4M shares at $1.90 in offering

2025-10-23T12:35:29.000Z - 11 months ago

Spectral AI prices 4M shares at $1.90 in offering


Spectral AI raises $7.6 Million of Additional Growth Capital

Oct 23, 2025, 8:30 AM EDT - 11 months ago

Spectral AI raises $7.6 Million of Additional Growth Capital


Spectral AI Earnings Call Transcript: Q2 2025

Aug 12, 2025, 5:00 PM EDT - 1 year ago

Spectral AI Earnings Call Transcript: Q2 2025


Spectral AI Quarterly report: Q2 2025

Aug 12, 2025, 5:00 PM EDT - 1 year ago

Spectral AI Quarterly report: Q2 2025


Spectral AI Earnings release: Q2 2025

Aug 12, 2025, 5:00 PM EDT - 1 year ago

Spectral AI Earnings release: Q2 2025


Spectral AI reports Q2 EPS (31c) vs. (16c) last year

2025-08-12T20:06:31.000Z - 1 year ago

Spectral AI reports Q2 EPS (31c) vs. (16c) last year


Spectral AI Announces 2025 Second Quarter Financial Results

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Spectral AI Announces 2025 Second Quarter Financial Results


Spectral AI appoints Stanley Micek as COO

2025-05-30T12:05:22.000Z - 1 year ago

Spectral AI appoints Stanley Micek as COO


Spectral AI Earnings Call Transcript: Q1 2025

May 13, 2025, 5:00 PM EDT - 1 year ago

Spectral AI Earnings Call Transcript: Q1 2025


Spectral AI Quarterly report: Q1 2025

May 13, 2025, 5:00 PM EDT - 1 year ago

Spectral AI Quarterly report: Q1 2025


Spectral AI Earnings release: Q1 2025

May 13, 2025, 5:00 PM EDT - 1 year ago

Spectral AI Earnings release: Q1 2025


Spectral AI Announces 2025 First Quarter Financial Results

May 13, 2025, 4:05 PM EDT - 1 year ago

Spectral AI Announces 2025 First Quarter Financial Results


Spectral AI Registration statement: Registration Filing

May 7, 2025, 8:00 AM EDT - 1 year ago

Spectral AI Registration statement: Registration Filing


Spectral AI Registration statement: Registration Filing

May 2, 2025, 8:00 AM EDT - 1 year ago

Spectral AI Registration statement: Registration Filing


Spectral AI Registration statement: Registration Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Spectral AI Registration statement: Registration Filing


Spectral AI Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Spectral AI Proxy statement: Proxy Filing


Spectral AI Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Spectral AI Proxy statement: Proxy Filing


Spectral AI Earnings Call Transcript: Q4 2024

Mar 27, 2025, 5:00 PM EDT - 1 year ago

Spectral AI Earnings Call Transcript: Q4 2024


Spectral AI Annual report: Q4 2024

Mar 27, 2025, 5:00 PM EDT - 1 year ago

Spectral AI Annual report: Q4 2024


Spectral AI Earnings release: Q4 2024

Mar 27, 2025, 5:00 PM EDT - 1 year ago

Spectral AI Earnings release: Q4 2024


Spectral AI Completes Three Device Installations in Australia

Mar 6, 2025, 10:36 AM EST - 1 year ago

Spectral AI Completes Three Device Installations in Australia


Spectral AI Provides Update to Investors

Jan 22, 2025, 8:00 AM EST - 1 year ago

Spectral AI Provides Update to Investors


afterhoursearnings
afterhoursearnings Sep. 19 at 12:58 AM
$MDAI intraday time frames looking quite strong in terms of stochisstics, moving average crosses, A/D, and ADX. Hit our head on the 50ema on the daily. If we pop that with some force maybe we get some follow through on the weekly to the 200ema (around 4).
0 · Reply
MoneySwell
MoneySwell Sep. 18 at 8:06 PM
$MDAI Interesting… 105,000 shares (half the day’s volume) traded in the last 15 minutes. Pushing the price up to close near the high of the day.👍🏼
1 · Reply
MoneySwell
MoneySwell Sep. 18 at 3:41 PM
$MDAI Spectral Al Showcases DeepView® System for Burn Indication and KOL Research at Southern Regional Burn Conference (SRBC). ( held September 10-12, 2026 in Williamsburg, Virginia.) Upcoming events: Midwest Region Burn Conference (MRBC) October 22-23, 2026 Columbus, OH Northeast Region Burn Conference (NRBC) November 13-14, 2026 Boston, MA https://finance.yahoo.com/healthcare/articles/spectral-ai-showcases-deepview-system-201500677.html
0 · Reply
CorbettCM
CorbettCM Sep. 18 at 3:19 PM
0 · Reply
Latinoheart
Latinoheart Sep. 18 at 10:07 AM
$MDAI @CorbettCM Spectral IP was created in 2024 as a separately funded intellectual-property venture, supported by a $1 million loan from its largest shareholder. Management presented it as a potential source of additional shareholder value without using capital earmarked for the core DeepView business. The company later proposed spinning off Spectral IP and distributing shares to Spectral AI shareholders. A March 2025 SEC filing expanded the plan, outlining an IPO, patent-related investments, licensing opportunities and other IP-focused activities. However, the proposed IPO and shareholder distribution never occurred. In July 2026, Spectral IP withdrew its registration statement and confirmed no securities had been sold. As a result, key questions remain unanswered: the status of the original $1 million loan, what assets and transactions were completed, Spectral AI's current ownership and economic interest in Spectral IP, and whether any alternative plans remain under consideration.
0 · Reply
Latinoheart
Latinoheart Sep. 18 at 10:02 AM
$MDAI @CorbettCM Strategic and commercial relationships. Spectral AI has highlighted the development of strategic relationships with government and commercial partners as an important part of its growth strategy. In August 2026, the company reported receiving $31.7 million in advanced BARDA funding and confirmed completion of all remaining milestones under its MTEC contract, including delivery of a functioning handheld DeepView prototype. These achievements are significant but should be distinguished from commercial product sales and private-sector distribution agreements. Based on the public announcements reviewed, I have not identified a disclosed material distribution agreement, minimum-purchase commitment, or separately reported commercial product revenue linked to a named commercial partner. The available public information does not allow shareholders to assess the commercial value, expected revenue, or maturity of the partnerships referenced.
0 · Reply
Latinoheart
Latinoheart Sep. 18 at 10:00 AM
$MDAI @CorbettCM Four DeepView platforms. In March 2025, management stated that it believed the company was on the proper path to generate commercial revenue from four separate DeepView platforms covering burns and other indications within three years. That remains a forward-looking objective. On the announced timetable, the three-year period had not expired by 14 September 2026. The materials reviewed do not, however, provide a simple platform-by-platform explanation identifying all four platforms and setting out the development, regulatory and commercial position of each one. Clear milestones for each platform would help shareholders assess progress without treating a long-term objective as either completed or missed before the stated period has expired.
0 · Reply
Latinoheart
Latinoheart Sep. 18 at 9:59 AM
$MDAI @CorbettCM Wound measurement. Management also stated in November 2023 that it intended to submit applications during 2024 for FDA, UKCA and CE-mark approval of 3D wound-measurement capabilities, subject to completion of the relevant development and regulatory work. Later company announcements referred to continuing technology development, including completion of a proof-of-concept module for calculating the total body surface area of a burn. However, the public filings and announcements reviewed do not clearly confirm the outcome of all the regulatory applications contemplated for wound measurement or identify a separately commercialised wound-measurement product. This does not prove that the programme has ended. It means that shareholders would benefit from a direct update on its regulatory position, remaining development work and commercial timetable.
0 · Reply
Latinoheart
Latinoheart Sep. 18 at 9:58 AM
$MDAI @CorbettCM DeepView for diabetic foot ulcers was a key part of Spectral AI’s post-SPAC growth strategy. In November 2023, management stated that it expected to submit FDA, UKCA and CE-mark applications for the DeepView DFU indication during 2024. By May 2024, the company reported completion of enrolment in its US DFU training study, expected completion of the validation study in the second half of 2024, and completion of a separate 76-patient study in Ireland. Current company materials continue to highlight the DFU opportunity and state that DeepView achieved 86% accuracy in predicting whether a DFU would achieve 50% wound closure by week four. However, based on publicly available information reviewed, it is unclear whether the FDA, UKCA and CE-mark applications anticipated for 2024 were submitted, approved, or remain under review. The current regulatory status, development timeline and route to commercialisation are not clearly disclosed.
0 · Reply
Latinoheart
Latinoheart Sep. 18 at 9:54 AM
$MDAI @CorbettCM Commercial revenue timeline. Since its September 2023 Nasdaq listing, Spectral AI has repeatedly linked DeepView commercialisation to near-term revenue. In 2023, management indicated a potential launch as early as 2024, subject to approvals. Following UKCA authorisation in February 2024, the company stated that UK sales could begin and expected commercial revenue during H2 2024. This expectation was reiterated in May 2024. By March 2025, management instead guided to first commercial product revenue in H2 2025. In May 2026, the FDA granted De Novo clearance for DeepView's burn indication, enabling US commercial distribution. The company subsequently stated it expects first US commercial sales by the end of 2026. These milestones relate to different markets and revenue categories, so they are not directly comparable. However, investors would benefit from clearer disclosure on the outcome of the UK revenue expectations announced for 2024 and discussed in 2025.
0 · Reply
Latinoheart
Latinoheart Sep. 18 at 9:49 AM
$MDAI @CorbettCM A clear account of what has been completed, delayed, changed or discontinued would allow shareholders to assess the company’s current position without relying on incomplete or disconnected announcements. I'll expand separetely but I am referring to: Commercial revenue timeline, DeepView for diabetic foot ulcers, Wound measurement, Four DeepView platforms, Strategic and commercial relationships, Formation and financing of Spectral IP and the proposed spin-off, public offering, shareholder distribution of Spectral IP. The public information shows that Spectral AI has achieved important regulatory, technical and government-funding milestones; including UKCA authorisation for the burn indication, FDA De Novo classification for the DeepView System for burns and continued BARDA support. However, the same public record also shows that some commercial and corporate objectives moved beyond their initial timetables or developed differently from the route first announced.
0 · Reply
ThePassiveEarner
ThePassiveEarner Sep. 18 at 8:11 AM
0 · Reply
CorbettCM
CorbettCM Sep. 17 at 10:22 PM
$MDAI I’m sure some of you here have been an unfortunate witness to my back and forth with this… let’s go with “character “ over the last weeks. I have no idea what his intent is, but I can say with certainty that he is completely fraudulent and has time and time again failed to substantiate anything he has ever tried to insult me or challenge me with. I would recommend ignoring any posts from this account lest ye fall victim to the endless rabbit hole of nonsense that I did. If anyone has any questions regarding MDAI, you’re welcome to reach out. I was there in NY. Cheers.
1 · Reply
KTGAMBLESTOCKS
KTGAMBLESTOCKS Sep. 17 at 6:58 PM
$MDAI I have a feeling it breaks $2 end of the month to start a rally to like 4.50 on anticipation of commercial revenue. (then will probably tank when we find out that means only one install, but thats later)
1 · Reply
afterhoursearnings
afterhoursearnings Sep. 17 at 4:58 PM
$MDAI bollingers on the daily haven't been this tight in a long time. Stochastics on weekly and daily both look bullish. Some volume could send it.
1 · Reply
cryptobythelake
cryptobythelake Sep. 17 at 4:40 PM
$MDAI PP continued: Ahead1 By year end 2026 First commercial sales targeted Late 2026 MTEC Phase 3 selection expected November 2026 CMS final rule on Category III code 0972T Through June 2027 Planned deployment of up to 30 systems with BARDA subsidy June 2027 Label Expansion for heads, hands & feet, UKCA Expanded approval, Initial Overseas sales 1. Reflects milestones previously disclosed publicly. Forward-looking statements are not guarantees of future performance and timing may change. 2027-2028 Expanded US and Overseas sales
0 · Reply
cryptobythelake
cryptobythelake Sep. 17 at 4:36 PM
$MDAI From the PP DeepView is now itself THE predicate. DeepView detected 88% of non-healing burns, while unaided clinical assessment missed 58% at initial presentation. DeepView more than doubles non-healing detection rates. Reproducibility of assessment of wound segmentation from Dice Score shows a consistency not found in clinician evaluation. A category with no predicate FDA granted De Novo classification because no legally marketed device wassubstantially equivalent. DeepView® is now itself the predicate. Confirmed in a multi-reader study Clinicians reading the same cases were more accurate overall, and detected more non-healing tissue, when using DeepView than when reading unaided — with no loss of specificity
0 · Reply
cryptobythelake
cryptobythelake Sep. 17 at 3:20 PM
$MDAI Spectral AI new Investor presentation VERY comprehensive. https://investors.spectral-ai.com/static-files/ddbbb98d-bd64-43fc-a33d-4bdde750dee4
0 · Reply
pi828
pi828 Sep. 16 at 10:43 PM
$MDAI the blip in AH trading could be because of this: https://www.stocktitan.net/news/MDAI/spectral-ai-showcases-deep-view-system-for-burn-indication-and-kol-ksspbsyk4uxf.html
1 · Reply
KTGAMBLESTOCKS
KTGAMBLESTOCKS Sep. 16 at 9:53 PM
$JTAI looks similar drifting like $MDAI could be explosive if buyers show up
0 · Reply
KTGAMBLESTOCKS
KTGAMBLESTOCKS Sep. 16 at 8:05 PM
$MDAI adding more as it goes to low 1.40s or if breaks 1.65 area with volume.
0 · Reply
KTGAMBLESTOCKS
KTGAMBLESTOCKS Sep. 16 at 5:33 PM
$MDAI well shit. I added a few more at this price.
0 · Reply